Protalix BioTherapeutics, Inc. (PLX) Revenue & Earnings 2020-2026

Revenue, EBITDA, operating income, net income, EPS, and shares

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares across quarters

TTM Revenue: $80.62M
Q. Revenue: $19.90M
TTM EBITDA: $25.59M
TTM Op. Income: $23.29M
Q. Op. Income: $4.67M
TTM Net Income: $18.95M
Q. Net Income: $3.78M
EPS: $0.05
Shares Out.: $79.99M

$80.62M in TTM revenue grew 30.1% YoY, reaching $19.90M last quarter. TTM EBITDA of $25.59M and TTM operating income of $23.29M show growth is flowing through to the bottom line. TTM net income of $18.95M means revenue is converting into profit.

TTM Revenue

Reveals whether the core business is growing or shrinking

Quarterly Revenue

Highlights seasonal patterns and short-term momentum

TTM EBITDA

Shows if underlying operating profitability is improving

Quarterly EBITDA

Tracks near-term operating profitability trends

TTM Operating Income

Smoothed operating profit over the past four quarters

Quarterly Operating Income

Profit from core operations before financing costs

TTM Net Income

The bottom line — is the company making more money?

Quarterly Net Income

Short-term profit after all expenses and taxes

EPS

Earnings per share — profit attributable to each share

Shares Outstanding

Declining means buybacks benefit remaining holders